

ASX ANNOUNCEMENT 18 JANUARY 2024

Placement of Entitlement Offer Shortfall

- Placement of Entitlement Offer Shortfall of approx. \$3.20m from institutional and sophisticated investors
- Takes the total amount subscribed under the entitlement offer and entitlement offer shortfall placement to \$7.66m (before costs)
- Current approximate cash position of \$15m¹ which will fund the advancement of the Company's clinical trials programs in Glioblastoma, Gastrointestinal Tumours and Acute Myeloid Leukemia

Sydney, Australia, 18 January 2024: Chimeric Therapeutics Limited (ASX:CHM, Chimeric or the Company), an Australian leader in cell therapy, announced on 25 October 2023 a non-renounceable entitlement Offer providing eligible shareholders an opportunity to subscribe for 2 new fully paid ordinary shares in Chimeric (New Shares) for every 3 fully paid ordinary shares in Chimeric at the issue price of \$0.028 per New Share.

The results of the Entitlement Offer were announced on 7 December 2023, which raised approximately \$4.5 million (before costs).

The Company is pleased to advise it has received commitments totalling approximately A\$3.20 million for the Shortfall under the Entitlement Offer. The 114,317,500 new fully paid ordinary shares (Shares) will be issued at the same price per Share as the Entitlement Offer being \$0.028 per Share and will rank equally in all respects with existing Shares on issue. Following the completion of this placement, the company does not intend to place any further shortfall under the entitlement offer.

On completion of the placement of the Shortfall, the Entitlement Offer raised approximately \$7.66 million (before costs). Funds will be used to advance the Phase 1B Clinical Trial in Glioblastoma, Phase 1A Clinical Trial in Gastrointestinal Tumours and to support the Phase 1B ADVENT-AML Clinical Trial at the University of Texas, MD Anderson Cancer Center.

CEO, Jennifer Chow said, "Following the strong support from our shareholders in the entitlement offer, we are very pleased to announce this shortfall placement. Together with the funds received from our recently announced R&D tax rebate of \$7.36m, the Company is now in an excellent position to deliver on key clinical milestones in 2024. We truly appreciate the ongoing confidence and conviction our shareholders have shown in our programs, our pipeline and our team."

¹ Including R&D rebate, Lind Placement as announced in January 2024 and Entitlement Offer Receipts



Indicative timetable

Event	Sydney, Australia Time
Placement announced on the ASX	Thursday, 18 January 2024
Settlement of Placement Shares	Tuesday, 23 January 2024
Allotment of Placement Shares	Wednesday, 24 January 2024

Note: This timetable is indicative only and subject to change. The Company reserves the right to vary the above dates and times, subject to the ASX Listing Rules and the Corporations Act.

ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer. We believe that cellular therapies have the promise to cure cancer, not just delay disease progression.

To bring that promise to life for more patients, Chimeric's world class team of cell therapy pioneers and experts is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.

Chimeric currently has a diversified portfolio that includes first in class autologous CAR T cell therapies and best in class allogeneic NK cell therapies. Chimeric assets are being developed across multiple different disease areas in oncology with 3 current clinical programs and plans to open additional clinical programs in 2023.

CHM 1101 (CLTX CAR T) is a novel and promising CAR T therapy developed for the treatment of patients with solid tumours. CHM 1101 is currently being studied in a phase 1B clinical trial in recurrent / progressive glioblastoma. Positive preliminary data from the investigator-initiated phase 1A trial in glioblastoma was announced in October 2023.

CHM 2101 (CDH17 CAR T) is a first-in-class, 3rd generation CDH17 CAR T invented at the world-renowned cell therapy centre, the University of Pennsylvania. Preclinical evidence for CHM 2101 was published in March 2022 in Nature Cancer demonstrating complete eradication of tumors in 7 types of cancer. CHM 2101 (CDH17 CAR T) received FDA IND clearance in November 2023 with a planned phase 1A clinical trial in gastrointestinal and neuroendocrine tumours opening in 2024.

CHM 0201 (CORE-NK platform) is a potentially best-in-class, clinically validated NK cell platform. Data from the complete phase 1A clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. Based on the promising activity signal demonstrated in that trial, the Phase 1B ADVENT-AML clinical trial investigating CHM 0201 in combination with Azacitidine and Venetoclax in patients with Acute Myeloid Leukemia was initiated in late 2024 at the University of Texas, MD Anderson Cancer Center. From the CHM 0201 platform, Chimeric also initiated development and has recently shown initial preclinical activity of CHM 0301, an armoured next generation NK cell platform and CHM 1301, an allogeneic CLTX CAR NK.



Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.

CONTACT

Investors

Jennifer Chow

Chief Executive Officer and Managing Director Executive Chairman

Chimeric Therapeutics

T: + 1 9087238387

E: jchow@chimerictherapeutics.com

W: www.chimerictherapeutics.com

<u>Media</u>

Matthew Wright

NWR Communications

P: +61 451 896 420

E: matt@nwrcommunications.com.au

Paul Hopper

Chimeric Therapeutics

T: + 61 406 671 515

E: paulhopper@lifescienceportfolio.com